TY - JOUR
T1 - Systemic transsulfuration pathway thiol concentrations in chronic obstructive pulmonary disease patients
AU - Zinellu, Angelo
AU - Zinellu, Elisabetta
AU - Sotgiu, Elisabetta
AU - Fois, Alessandro G.
AU - Paliogiannis, Panagiotis
AU - Scano, Valentina
AU - Piras, Barbara
AU - Sotgia, Salvatore
AU - Mangoni, Arduino A.
AU - Carru, Ciriaco
AU - Pirina, Pietro
PY - 2020/8
Y1 - 2020/8
N2 - Background: It is amply reported that patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular disease (CVD). Recent evidence suggests that COPD patients have elevated concentrations of plasma homocysteine (Hcy), a transsulfuration pathway analyte that is commonly regarded as a CVD risk factor. Design: We comprehensively investigated the plasma concentrations of transsulfuration pathway analytes, and their relationship with markers of oxidative stress and inflammation, to identify which low molecular thiols might play a pathophysiological role both in CVD and in COPD. Hcy, cysteine (Cys), glutathione (GSH), cysteinylglycine (CysGly), glutamylcysteine (GluCys), taurine (Tau), oxidative stress markers (TBARS and protein-SH, PSH) and the inflammation marker kynurenine/tryptophan (Kyn/Trp) ratio were measured in 54 COPD patients and 54 control subjects. Results: We found increased concentrations of total Hcy (P <.01) and total CysGly (P <.05) in COPD patients when compared to controls. Total Hcy and CysGly were also significantly associated with abnormal lung function parameters and COPD severity. In COPD patients, total Hcy was significantly associated with the Kyn/Trp ratio (P =.0017) whereas total CysGly was significantly associated with both PSH (P =.0298) and the Kyn/Trp ratio (P = <.0001). Conclusion: Both total Hcy and CysGly concentrations were significantly associated with the presence and severity of COPD and with markers of oxidative stress (total CysGly) and inflammation (total Hcy and CysGly). This suggests that specific low molecular mass thiols might play a role in the inflammatory and oxidative stress pathways involved in both CVD and COPD.
AB - Background: It is amply reported that patients with chronic obstructive pulmonary disease (COPD) have increased risk of cardiovascular disease (CVD). Recent evidence suggests that COPD patients have elevated concentrations of plasma homocysteine (Hcy), a transsulfuration pathway analyte that is commonly regarded as a CVD risk factor. Design: We comprehensively investigated the plasma concentrations of transsulfuration pathway analytes, and their relationship with markers of oxidative stress and inflammation, to identify which low molecular thiols might play a pathophysiological role both in CVD and in COPD. Hcy, cysteine (Cys), glutathione (GSH), cysteinylglycine (CysGly), glutamylcysteine (GluCys), taurine (Tau), oxidative stress markers (TBARS and protein-SH, PSH) and the inflammation marker kynurenine/tryptophan (Kyn/Trp) ratio were measured in 54 COPD patients and 54 control subjects. Results: We found increased concentrations of total Hcy (P <.01) and total CysGly (P <.05) in COPD patients when compared to controls. Total Hcy and CysGly were also significantly associated with abnormal lung function parameters and COPD severity. In COPD patients, total Hcy was significantly associated with the Kyn/Trp ratio (P =.0017) whereas total CysGly was significantly associated with both PSH (P =.0298) and the Kyn/Trp ratio (P = <.0001). Conclusion: Both total Hcy and CysGly concentrations were significantly associated with the presence and severity of COPD and with markers of oxidative stress (total CysGly) and inflammation (total Hcy and CysGly). This suggests that specific low molecular mass thiols might play a role in the inflammatory and oxidative stress pathways involved in both CVD and COPD.
KW - cardiovascular disease
KW - chronic obstructive pulmonary disease
KW - cysteinylglycine
KW - homocysteine
KW - inflammation
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85085045790&partnerID=8YFLogxK
U2 - 10.1111/eci.13267
DO - 10.1111/eci.13267
M3 - Article
C2 - 32378181
AN - SCOPUS:85085045790
VL - 50
JO - EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
JF - EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
SN - 0014-2972
IS - 8
M1 - e13267
ER -